SB 206553 hydrochloride

Pricing Availability   Qty
说明: Potent and selective 5-HT2B and 5-HT2C antagonist; orally active
化学名: 3,5-Dihydro-5-methyl-N-3-pyridinylbenzo[1,2-b:4,5-b']dipyrrole-1(2H)-carboxamide hydrochloride
纯度: ≥99% (HPLC)
说明书
引用文献 (9)
评论 (1)
文献 (3)

生物活性 for SB 206553 hydrochloride

SB 206553 hydrochloride is a potent and selective 5-HT2B/5-HT2C receptor antagonist (rat 5-HT2B pA2 = 8.89, human 5-HT2C pKi = 7.92). Displays > 80-fold selectivity over all other 5-HT receptor subtypes and a variety of other receptors (pKi < 6). Centrally active following oral administration in vivo.

许可信息

Sold for research purposes under agreement from GlaxoSmithKline

化合物库 for SB 206553 hydrochloride

SB 206553 hydrochloride is also offered as part of the Tocriscreen 2.0 Max. 了解 Tocris 化合物库的更多信息。

技术数据 for SB 206553 hydrochloride

分子量 328.8
公式 C17H16N4O.HCl
储存 Desiccate at RT
纯度 ≥99% (HPLC)
CAS Number 1197334-04-5
PubChem ID 11957707
InChI Key VGEMBOFBPSNOIO-UHFFFAOYSA-N
Smiles Cl.CN1C=CC2=CC3=C(CCN3C(=O)NC3=CC=CN=C3)C=C12

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

溶解性数据 for SB 206553 hydrochloride

溶剂 最高浓度 mg/mL 最高浓度 mM
溶解性
DMSO 32.88 100

制备储备液 for SB 206553 hydrochloride

以下数据基于产品分子量 328.8。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

选择批次从而根据批次分子量重新计算:
浓度/溶剂体积/质量 1 mg 5 mg 10 mg
1 mM 3.04 mL 15.21 mL 30.41 mL
5 mM 0.61 mL 3.04 mL 6.08 mL
10 mM 0.3 mL 1.52 mL 3.04 mL
50 mM 0.06 mL 0.3 mL 0.61 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

产品说明书 for SB 206553 hydrochloride

分析证书/产品说明书
选择另一批次:

参考文献 for SB 206553 hydrochloride

参考文献是支持产品生物活性的出版物。

Forbes et al (1995) 5-Methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2,3-f]indole: a novel 5-HT2C/5-HT2B receptor antagonist with improved affinity, selectivity and oral activity. J.Med.Chem. 38 2524 PMID: 7629791

Kennett et al (1996) In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties. Br.J.Pharmacol. 117 427 PMID: 8821530

Porras et al (2002) 5-HT2A and 5-HT2C/2B receptor subtypes modulate DA release induced in vivo by amphetamine and mor. in both the rat nucleus accumbens and striatum. Neuropsychopharmacology 26 311 PMID: 11850146


If you know of a relevant reference for SB 206553 hydrochloride, please let us know.

按产品操作查看相关产品

查看全部 5-HT2C Receptor Antagonists

关键词: SB 206553 hydrochloride, SB 206553 hydrochloride supplier, Potent, selective, 5-HT2C/5-HT2B, antagonists, Serotonin, 5-HT2B, Receptors, 5-HT2C, SB206553, hydrochloride, GlaxoSmithKline, GSK, 1661, Tocris Bioscience

9 篇 SB 206553 hydrochloride 的引用文献

引用文献是使用了 Tocris 产品的出版物。 SB 206553 hydrochloride 的部分引用包括:

Fouad et al (2010) Locomotion after spinal cord injury depends on constitutive activity in serotonin receptors. J Neurophysiol 104 2975 PMID: 20861436

Canal et al (2010) The serotonin 2C receptor potently modulates the head-twitch response in mice induced by a phenethylamine hallucinogen. Psychopharmacology (Berl) 209 163 PMID: 20165943

Murray et al (2010) Recovery of motoneuron and locomotor function after spinal cord injury depends on constitutive activity in 5-HT2C receptors. Nat Med 16 694 PMID: 20512126

Li et al (2014) Synthesis, transport, and metabolism of serotonin formed from exogenously applied 5-HTP after spinal cord injury in rats. J Neurophysiol 111 145 PMID: 24068759


您是否知道使用了 Tocris SB 206553 hydrochloride 的优秀论文? 请告知我们.

SB 206553 hydrochloride 的评论

平均评分: 5 (Based on 1 Review.)

5 星
100%
4 星
0%
3 星
0%
2 星
0%
1 星
0%

Have you used SB 206553 hydrochloride?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Effects of SB-206553 on MDMA-induced changes in dorsal striatal electrophysiology.
By Kevin Ball on 01/25/2019
分析类型: In Vivo
种属: Rat

We assessed the effect of SB-206553 (2.0 mg/kg, s.c.) on dorsal striatal single-unit electrophysiology following MDMA (ecstasy; 5.0 mg/kg) administration. A coefficient-of-variation analysis indicated significantly less variability in the magnitude of both MDMA-induced neuronal excitations and inhibitions in rats that were pretreated with SB-206553 compared to vehicle (shown in figure).

PMID: 16001122 参考文献
review image

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。


5-HT Receptors Scientific Review

5-HT Receptors Scientific Review

Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.